focus -WSS

focus

author：focus 2025-08-12 09:11:09 - browse：18342

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Medicare says breakthrough device reimbursement rule to come by summer

WSS

5 to watch: Tech startups trying to solve health care's staffing crisis

Future doctors should be trained to promote social change

Colonoscopy prep: Liquid

Readout Newsletter: Bluebird, CVS, Contineum

Steward Health Care files for bankruptcy

Software glitch causes Tandem insulin pump to shutdown, FDA warns

entertainment

focus

hotspot

New air purifier tech could be key to improving indoor air quality

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Duchenne breakthrough therapy leaves behind pioneering families

Nurses recount patients attacks

Tori Bowie and the unacceptable rates of Black maternal death

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

The high cost of giving birth even with insurance

Physicians and social media: If you see something, say something?

knowledge

Researchers on aging grapple with how to calculate biological age

Brain worms: The science behind RFK Jr.'s parasitic infection

Asbestos, a deadly carcinogen, banned by EPA

Google says AlphaFold 3 can map a vast universe of biomolecules

Intermittent fasting comes with a heart risk? Not so fast

5 to watch: Tech startups trying to solve health care's staffing crisis

focus

hotspot

hotspot

focus